iPS Cells of Patients for Models of Retinal Dystrophies (RETIPS)
Primary Purpose
Retinal Dystrophies
Status
Recruiting
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Skin biopsy
Sponsored by
About this trial
This is an interventional other trial for Retinal Dystrophies
Eligibility Criteria
Inclusion criteria :
- Signed informed consent and
Choroideremia :
- Males
- CHM mutation
- With multimodal Imaging anomalies in line with CHM
- All other presumed inherited retinal dystrophies with bilateral and symmetrical involvement with identified mutations in one of the Retnet gene
- All presumed inherited optic neuropathy with bilateral and symmetrical involvement with identified mutations
And in all cases or pattern
- Age from 5 to 70
- with appropriate health insurance
Exclusion criteria :
- Patient under tutorship or curatorship
Sites / Locations
- CNMR Maolya, Genetic Sensory DiseasesRecruiting
Arms of the Study
Arm 1
Arm Type
Other
Arm Label
Skin biopsy
Arm Description
Outcomes
Primary Outcome Measures
number of human cell models obtained
Secondary Outcome Measures
Full Information
NCT ID
NCT03853252
First Posted
February 22, 2019
Last Updated
December 18, 2022
Sponsor
University Hospital, Montpellier
Collaborators
Institut National de la Santé Et de la Recherche Médicale, France
1. Study Identification
Unique Protocol Identification Number
NCT03853252
Brief Title
iPS Cells of Patients for Models of Retinal Dystrophies
Acronym
RETIPS
Official Title
iPS Cells of Patients for Models of Retinal Dystrophies
Study Type
Interventional
2. Study Status
Record Verification Date
December 2022
Overall Recruitment Status
Recruiting
Study Start Date
November 3, 2014 (Actual)
Primary Completion Date
November 2024 (Anticipated)
Study Completion Date
November 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Montpellier
Collaborators
Institut National de la Santé Et de la Recherche Médicale, France
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The investigators are focused on inherited retinal dystrophies with an aim to further understand disease pathophysiology and to elaborate novel treatments, as, to date, there is no effective treatment to prevent blindness.
The main goal of this study is to generate human cellular models of healthy and disease retinas and perform studies to evaluate the efficiency of gene therapy approaches for different diseases.
Skin biopsies of volunteers are cultured to isolate fibroblasts that are then reprogrammed into iPS cells. Healthy and disease-specific iPS cells are then differentiated into retinal models.
This study should help to elucidate disease pathways and to provide proof-of-concept for various therapeutic approaches.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Retinal Dystrophies
7. Study Design
Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
150 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Skin biopsy
Arm Type
Other
Intervention Type
Other
Intervention Name(s)
Skin biopsy
Intervention Description
Skin biopsy on a location preliminarily anesthetized Disinfection protocol Combined required blood tests (HIV, Hepatitis B)
Primary Outcome Measure Information:
Title
number of human cell models obtained
Time Frame
10 years
10. Eligibility
Sex
All
Minimum Age & Unit of Time
5 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria :
Signed informed consent and
Choroideremia :
Males
CHM mutation
With multimodal Imaging anomalies in line with CHM
All other presumed inherited retinal dystrophies with bilateral and symmetrical involvement with identified mutations in one of the Retnet gene
All presumed inherited optic neuropathy with bilateral and symmetrical involvement with identified mutations
And in all cases or pattern
Age from 5 to 70
with appropriate health insurance
Exclusion criteria :
Patient under tutorship or curatorship
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Vasiliki Kalatzis, PhD
Phone
(0)499636097
Ext
+33
Email
vasiliki.kalatzis@inserm.fr
Facility Information:
Facility Name
CNMR Maolya, Genetic Sensory Diseases
City
Montpellier
State/Province
Occitanie
ZIP/Postal Code
34294
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Isabelle MEUNIER, PhD
Phone
(0)467330278
Ext
+33
Email
isabelannemeunier@yahoo.fr
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
iPS Cells of Patients for Models of Retinal Dystrophies
We'll reach out to this number within 24 hrs